Piper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15

CAMP4 Therapeutics Corporation

CAMP4 Therapeutics Corporation

CAMP

0.00

Piper Sandler analyst Edward Tenthoff reiterates Camp4 Therapeutics (NASDAQ: CAMP) with a Overweight and raises the price target from $12 to $15.